Recent investigations have converged on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and DA communication. While GLP agonists are commonly employed for treating type 2 T2DM, their unexpected impacts on reinforcement circuits, specifica